Marshall Wace North America’s ChemoCentryx, Inc. CCXI Stock Holding History

Marshall Wace North America’s Portfolio CCXI Stock Details CCXI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-551,654	Closed	-$28.3M	–	1920
2021 Q1	$28.3M	Buy	551,654 +10,264	+2%	+$618K	0.12%	201
2020 Q4	$33.5M	Sell	541,390 -385,292	-42%	-$22.1M	0.15%	168
2020 Q3	$50.8M	Sell	926,682 -623,452	-40%	-$33.6M	0.33%	72
2020 Q2	$89.2M	Buy	1,550,134 +390,057	+34%	+$21.2M	0.59%	35
2020 Q1	$46.6M	Buy	1,160,077 +1,100,759	+1,856%	+$46.7M	0.35%	78
2019 Q4	$2.35M	Buy	59,318 +36,850	+164%	+$647K	0.01%	544
2019 Q3	$152K	Buy	+22,468	New	+$169K	﹤0.01%	999
2019 Q2	–	Sell	-16,938	Closed	-$235K	–	1762
2019 Q1	$235K	Buy	+16,938	New	+$194K	﹤0.01%	949

Other funds holding CCXI

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $23.5B AUM 33.24% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Marshall Wace North America's CCXI Position: Q2 2021 in Review

Marshall Wace North America sold out of ChemoCentryx, Inc. (CCXI) in Q2 2021, closing a stake of 551,654 shares — an estimated $28.3M sold.

Marshall Wace North America first reported a position in CCXI in Q1 2019 and held it in 8 quarters. The position peaked at $89.2M in Q2 2020. 147 funds tracked by Wall St. Rank hold CCXI as of Q2 2021.

Marshall Wace North America reported no remaining ChemoCentryx, Inc. position as of Q2 2021 after selling out during the quarter.
Marshall Wace North America sold 551,654 ChemoCentryx, Inc. shares in Q2 2021, an estimated $28.3M.
Marshall Wace North America first reported a position in ChemoCentryx, Inc. in Q1 2019 and held it in 8 quarters.
Marshall Wace North America's ChemoCentryx, Inc. position peaked at $89.2M in Q2 2020.
147 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q2 2021.

Based on Marshall Wace North America's 13F filing for Q2 2021, filed 13 Aug 2021.